red image shaped like a slash
Steve Curtis

Director, New Ventures

Director of New Ventures at BrightEdge — the impact venture capital arm of the ACS

Prior to joining ACS/BrightEdge, Steve managed MPM Capital’s Oncology Innovations Fund, a hybrid venture/philanthropy investment collaboration with Dana-Farber Cancer Institute. At MPM, he led the investments in seed and Series A stage biotech companies and held various interim operating roles in many of these start-ups. Steve also supported MPM’s partnership with a number of strategic investors.

Prior to joining MPM, Steve was Senior Director of Business Development for Eli Lilly and Company. In that role, he focused on Lilly’s limited partnerships in top-tier venture funds, direct equity investments and other “shared-risk” relationships with biotech companies. Prior to Lilly, Steve co-led the Bioscience Ventures group within 2M Companies, the Dallas-based family office of Morton H. Meyerson, focusing on early-stage private healthcare investments. Before 2M, he worked at Reata Pharmaceuticals, running the Technology Evaluation and In-Licensing program, where he led the in-licensing of an asset that is now in clinical development.

As a volunteer, Steve sits on the Allocation Advisory Board for the Follicular Lymphoma Foundation, the Advisory Committee for the IBD Ventures program for the Crohn’s & Colitis Foundation, and is an Expert Advisor for The Research Acceleration and Innovation Network (TRAIN) of the Milken Institute’s FasterCures division.

red image shaped like a slash